Please assess the completion status of the following clinical trial:

Trial Title: Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed non-Hodgkin's lymphoma~* CD20+ disease~* Failed at least 1 prior standard systemic therapy~* Persistent lymphoma by physical examination, radiographic studies, bone marrow evaluations, flow cytometry, or polymerase chain reaction~* Tumor burden less than 500 cc by computed tomography or MRI~  * No splenomegaly~* Autologous hematopoietic stem cells or bone marrow harvested and cryopreserved~  * No circulating lymphoma cells by morphology or flow cytometry at or near the time of peripheral blood stem cell (PBSC) collection if unpurged PBSCs are to be used~ * 10% or less marrow involvement by flow cytometry or morphology if purged bone marrow is to be used~* No CNS lymphoma~* No chronic lymphocytic leukemia or small lymphocytic lymphoma/well-differentiated lymphocytic lymphoma~PATIENT CHARACTERISTICS:~Age~* 60 to 80~Performance status~* SWOG 0-1~Life expectancy~* More than 60 days~Hematopoietic~* See Disease Characteristics~Hepatic~* Bilirubin less than 1.5 mg/dL~Renal~* Creatinine less than 2.0 mg/dL~Cardiovascular~* No active coronary artery disease~Pulmonary~* FEV_1 at least 70% of expected~* Vital capacity at least 70% of expected~Other~* Not pregnant~* Negative pregnancy test~* Fertile patients must use effective contraception~* HIV negative~* Able to perform self-care during radiation isolation~* No major organ dysfunction~* No major infection~* No circulating anti-mouse antibody~* No other serious medical condition considered to represent contraindications to bone marrow transplantation~* No competing causes of death that would predict life span to be less than 10 additional years~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior bone marrow or stem cell transplantation~Chemotherapy~* Not specified~Endocrine therapy~* Not specified~Radiotherapy~* No prior radiotherapy greater than 20 Gy to any critical normal organ (e.g., lung, liver, spinal cord, or more than 25% of red marrow)~Surgery~* Not specified~Other~* More than 30 days since prior systemic antilymphoma therapy

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).